Next-generation incretins: early signals beyond semaglutide, not yet like for like

This week's question

Two of this week's reports compare newer incretin-based agents with semaglutide. The question is whether the newer agents add anything beyond it. Three reports give partial answers. One is a meta-analysis of CagriSema in type 2 diabetes. One is a phase 2 trial of the triple agonist UBT251. One is a phase 3 trial of oral orforglipron in Japanese adults. Only the first two include semaglutide as a comparator, and they use different doses.

What the studies showed

CagriSema (six randomised trials, Bayesian meta-analysis). CagriSema combines cagrilintide with semaglutide. The review included six trials with 4554 potentially eligible participants with type 2 diabetes. Versus placebo, CagriSema 2.4 mg gave a between-group HbA1c difference of -1.87 percentage points (95% CrI, -2.08 to -1.62). The between-group difference in percentage body-weight change was -12.69 percentage points (95% CrI, -13.78 to -11.61). Versus semaglutide 2.4 mg, the additional HbA1c reduction was modest and uncertain (-0.21 percentage points; 95% CrI, -0.62 to 0.11), and the interval includes zero. The additional weight reduction remained probable (-5.84 percentage points; 95% CrI, -10.08 to -2.15). Gastrointestinal adverse events (RR, 2.27) and discontinuation because of adverse events (RR, 3.16; 95% CrI, 1.50 to 6.87) were more frequent than with placebo. Estimates against semaglutide were less precise.

UBT251 (phase 2, 211 Chinese adults with type 2 diabetes, 24 weeks). UBT251 is a once-weekly GLP-1, GIP and glucagon receptor agonist. At week 24, least-squares mean HbA1c changes were -2.16% to -1.98% across the UBT251 groups. They were -1.77% with 1 mg semaglutide and -0.66% with placebo. Placebo-adjusted differences for UBT251 ranged from -1.50% to -1.32% (all p < 0.001). Weight reduction with UBT251 was significantly greater than with placebo and with semaglutide (all p < 0.05). The abstract does not give the weight figures. Gastrointestinal events were the most common adverse events, but rates are not reported.

Orforglipron (phase 3, 238 Japanese adults with obesity, 72 weeks). Orforglipron is a once-daily oral, non-peptide GLP-1 receptor agonist. Type 2 diabetes was targeted at about 25% of participants. The mean bodyweight change at week 72 was -5.9% (6 mg), -8.7% (12 mg) and -7.9% (36 mg), against -0.6% with placebo (all p<0.0001). A reduction of at least 5% was reached by 45.6%, 60.8% and 58.8% of the three orforglipron groups, against 15.2% with placebo. The authors call the weight loss statistically superior to placebo. Side effects were mostly mild-to-moderate gastrointestinal symptoms. Nausea most often led to stopping: five of 60 (8%) in the 36 mg group, against none with placebo.

Where they agree and where they do not

Where they agree. All three agents lowered weight, and the two diabetes studies also lowered HbA1c. Gastrointestinal events were the most common adverse events in the UBT251 and orforglipron trials. In the CagriSema analysis, gastrointestinal adverse events (RR, 2.27) and adverse-event-related discontinuation were more frequent than with placebo, and comparative gastrointestinal tolerability versus semaglutide remains uncertain. All three rest on surrogate outcomes, not on cardiovascular or kidney events.

Where they cannot be compared. The studies differ in almost every way that matters:

• Population: adults with type 2 diabetes (CagriSema meta-analysis, UBT251) versus adults with obesity, with type 2 diabetes targeted at about 25% of participants (orforglipron). The UBT251 trial enrolled Chinese adults and the orforglipron trial Japanese adults.
• Comparator: placebo only for orforglipron. Placebo and 1 mg semaglutide for UBT251. Placebo and 2.4 mg semaglutide for CagriSema.
• Design and length: a pooled analysis of six trials, a 24-week phase 2 trial and a 72-week phase 3 trial.
• Endpoint: orforglipron's results are weight only. The other two report HbA1c and weight.

Because of this, the percentages above should not be lined up in one table. A larger weight fall in one study than in another says nothing about which drug is better. Orforglipron has no semaglutide result at all in these reports.

The two semaglutide comparisons also differ from each other. In the CagriSema analysis, the semaglutide arm was 2.4 mg and the HbA1c advantage was uncertain. In the UBT251 trial, the semaglutide arm was 1 mg. The abstract does not state whether UBT251's HbA1c was formally tested against semaglutide. Only the weight comparison is reported as significant. So a weight signal over semaglutide appears in both reports, but each is limited. The CagriSema interval is wide. The UBT251 abstract gives no weight figures.

What is still unknown

• Head-to-head evidence for orforglipron. The Japanese trial used placebo only. The abstract reports no formal comparison between the orforglipron doses, so the results at 12 mg and 36 mg should not be read as different from each other.
• Size of UBT251's weight advantage. Dose comparisons, dropouts, blinding, funding and the rates of gastrointestinal events or hypoglycaemia are not in the abstract.
• Tolerability against semaglutide. For CagriSema, the authors say comparative gastrointestinal tolerability and discontinuation risk remain uncertain. The meta-analysis abstract does not report heterogeneity, risk of bias, follow-up length or funding.
• Hard outcomes. None of the reports gives cardiovascular or other hard clinical outcomes. The CagriSema and UBT251 reports give no long-term safety data, and the orforglipron abstract does not report serious adverse events.
• Durability. The orforglipron abstract does not say what happens to weight after treatment stops. UBT251 was tested for only 24 weeks.
• Other populations. The UBT251 abstract reports no Indian data, and the orforglipron trial was done only in Japanese adults. The CagriSema abstract does not report where its trials were done.

For your clinic on Monday

Nothing here supports an individual treatment decision or a change in practice. The most useful points are these:

• CagriSema's extra weight effect over semaglutide 2.4 mg is probable but imprecise (95% CrI, -10.08 to -2.15). Its extra HbA1c effect is uncertain.
• UBT251 is a phase 2 finding that needs phase 3 confirmation. The authors themselves support that step.
• Orforglipron has shown superiority over placebo for weight in Japanese adults. It has not been compared with semaglutide.
• Gastrointestinal events were the most common reported adverse events with UBT251 and orforglipron, and were more frequent with CagriSema than with placebo.
• Read the full papers for adverse event tables and trial-level data before drawing firm conclusions.

India box. An expert committee of India's national drug regulator has recommended import and marketing permission for orforglipron. As of September 2026 there is no final approval and no launch. The CagriSema abstract does not state its regulatory status, so check local availability and labelling separately. Semaglutide is the comparator in two of the reports. Its Indian product patent expired on 20 March 2026 and a number of Indian manufacturers now make it. A separate formulation patent runs to 2031, so many Indian products come as vials or reusable cartridge pens. Most are approved for type 2 diabetes rather than for weight, and only a few carry a weight indication. Indian-made semaglutide runs from roughly ₹1,300 to about ₹8,000 a month depending on manufacturer, presentation and dose. Indicative pen prices in September 2026 run from about ₹5,660 at 0.25 mg to about ₹8,999 at 2.4 mg. The dearer originator brand runs to about ₹16,400 at 2.4 mg. (Indian availability and prices as checked in September 2026.)